Pre-made Carlumab biosimilar ( Whole mAb, anti-CCL2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-094
Anti-CCL2 therapeutic antibody (Pre-made Carlumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CCL2 therapeutic antibody (Pre-made Carlumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||4dn3:HL/4dn4:HL|
|95-98% SI Structure||None|
|Conditions Discontinued||Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours|
|Development Tech||Human Phage Display|